GE Healthcare Technologies Inc. (GEHC)

In early February 2026, GE HealthCare Technologies shares surged following a strong fourth-quarter earnings beat and optimistic 2026 guidance. The company's adjusted EBIT margin in Q4 2025 contracted due to tariff expenses, but 2026 tariff headwinds are expected to be lower. GE HealthCare has been engaged in strategic acquisitions, including the pending Intelerad deal. Earlier, GE HealthCare Technologies shares closed sharply lower following a downgrade to "Sell" by UBS. Over the last six months, GE HealthCare's shares have gained 13.4%, outperforming the industry's decline and the S&P 500's gain during the same period.

The provided search results do not explicitly detail the demand seasonality for GE HealthCare Technologies, Inc.'s products and services. However, reports mention resilient customer demand, a healthy capital equipment environment and increasing traction from recent product launches for Q4 2025, indicating consistent demand. Approximately half of GE HealthCare's revenue is recurring, stemming from servicing, pharmaceutical diagnostics, and digital solutions, which could suggest a degree of stability in demand.

GE HealthCare Technologies, Inc. is a global medical technology and pharmaceutical diagnostics company headquartered in Chicago, established in January 2023 after spinning off from General Electric. The company operates in the health technology sector, focusing on imaging and diagnostics. GE HealthCare develops, manufactures, and markets products, services, and digital solutions for patient diagnosis, treatment, and monitoring. The company's operations are structured across four main segments: Imaging, Advanced Visualization Solutions (AVS), Patient Care Solutions (PCS), and Pharmaceutical Diagnostics (PDx). The Imaging segment offers products like molecular imaging, CT scanning, MR imaging, X-ray systems, and women's health products. AVS provides ultrasound, image-guided therapies, and interventional solutions. PCS includes patient monitoring, diagnostic cardiology, consumables and services, digital solutions, maternal infant care, and anesthesia products. The PDx segment supplies diagnostic agents for CT, angiography, X-ray, MR, and molecular imaging.

GE HealthCare serves customers globally, operating in over 100 countries. The United States accounts for 46% of revenue, EMEA for 26%, China for 12%, and the rest of the world for 17%. Major regional operations are located in Buc, Helsinki, Kraków, Budapest, Yizhuang, Hino & Tokyo, and Bangalore, with Bangalore also housing its largest R&D center.

Explicit information detailing GE HealthCare Technologies, Inc.'s brand reputation as a specific metric or outlining events that negatively impacted its reputation in the past year is not readily available. However, the company's strong financial performance and emphasis on innovation and strategic acquisitions contribute to a positive perception. The mention of competitive risks by an analyst could be an indirect factor influencing perception, but it is not presented as a direct reputation-damaging event.

GE HealthCare Technologies Inc. is heavily dominated by institutional owners, who hold approximately 86% of the shares. Major institutional shareholders include The Vanguard Group, Inc., BlackRock, Inc., Dodge & Cox, Capital Research Global Investors and State Street Corp. Individual investors, or the general public, hold a 13% stake in the company.